Melatonina
Anno: 1999
-
Riferimento:Eur J Cancer. 1999 Nov;35(12):1688-92.Azione della melatonina:MLT (20 mg/day orally) may enhance the efficacy of chemotherapy and reduce its toxicity. Tumour response rate: 42/124 CT + MLT versus 19/126 CT (5-FU plus folinic acid) only.Target:Counteract chemotherapy toxicity.
-
Riferimento:Adv Exp Med Biol. 1999;467:217-26. Review.Azione della melatonina:Effect of MLT in combination with IL-2 or other cytokines in cancer patients and viral diseases including HIV-infected patients.Target:Interleukin-2 (IL-2).
-
Riferimento:Neuro Oncol. 1999 Jul;1(3):212-20.Azione della melatonina:Reasonable support for a causal role of EMF on brain cancer.Target:General review.
-
Titolo: Does winter darkness in the Artic protect against cancer? The melatonin hypothesis revisitedRiferimento:Med Hypotheses. 1999 Jul;53(1):1-5.Azione della melatonina:Research on a melatonin-inhibited carcinogenesis in the low-risk populations of the Arctic should be pursued.Target:Melatonin hypothesis.
-
Riferimento:Bioelectromagnetics. 1999 Sep;20(6):338-46.Azione della melatonina:Explanation for the observed ornithine decarboxylase (ODC) changes after magnetic fields (MF) exposure is the melatonin hypothesis.Target:50 Hz magnetic fields.
-
Riferimento:Life Sci. 1999;65(4):415-20.Azione della melatonina:Melatonin (1 nM) inhibits MCF-7 cell proliferation with an increased expression of p21WAF1 protein mediated by the p53 pathway.Target:p53/p21WAF1.
-
Titolo: Meditation and prostate cancer: integrating a mind/body intervention with traditional therapiesRiferimento:Semin Urol Oncol. 1999 May;17(2):111-8. Review.Azione della melatonina:Association between meditation practice and levels of melatonin which can influence breast and prostate tumors.Target:Psychoneuroimmunology.
-
Riferimento:Adv Exp Med Biol. 1999;460:407-9.Azione della melatonina:(No abstract available).Target:(No abstract available).
-
Riferimento:Adv Exp Med Biol. 1999;460:345-62. Review.Azione della melatonina:No abstract available.Target:No abstract available.
-
Riferimento:J Pineal Res. 1999 Apr;26(3):169-73Azione della melatonina:Melatonin (orally at 20 mg/day) may contribute to the realization of chemotherapy in metastatic cancer patients.Target:Thrombocytopenia.